<DOC>
	<DOCNO>NCT00819000</DOCNO>
	<brief_summary>The purpose study determine high compliance adherence rate drug therapy MS result well health outcome low rate therapy compliance adherence .</brief_summary>
	<brief_title>Therapy Optimization Multiple Sclerosis ( MS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>Male female , 18 year age old , diagnosis MS . Being treat Glatiramer Acetate ( GA ) ( IFN ) β Receiving therapy participate Specialty Pharmacy Has contraindication GA IFNβ therapy , include pregnancy , try become pregnant , breast feeding study Has receive experimental drug last thirty ( 30 ) day Fampridine SR ( 4aminopyridine 4AP ) Unlikely able participate full two year study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Specialty Pharmacy</keyword>
	<keyword>Therapy Management</keyword>
	<keyword>Medication Compliance</keyword>
	<keyword>Medication Adherence</keyword>
	<keyword>Medication Persistence</keyword>
	<keyword>Health Outcomes</keyword>
</DOC>